65 patents
Page 4 of 4
Utility
Dosing of Cabozantinib Formulations
27 May 20
The invention relates to administration of various pharmaceutical formulations of N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, (cabozantinib) a c-Met inhibitor, and its metabolites, to achieve desirable pharmacokinetic and pharmacodynamic effects.
Dana T. Aftab, Sriram Naganathan, Wei Xu, Steven Lacy
Filed: 28 Jan 20
Utility
C-Met Modulator Pharmaceutical Compositions
22 Apr 20
Jo Ann Wilson, Khalid Shah
Filed: 19 Dec 19
Utility
Processes for Preparing Quinoline Compounds and Pharmaceutical Compositions Containing Such Compounds
8 Apr 20
Jo Ann Wilson, Khalid Shah
Filed: 5 Dec 19
Utility
Mek Inhibitors and Methods of Their Use
29 Jan 20
Disclosed are compounds of Formula (I) and pharmaceutically acceptable salts and solvates thereof.
Naing Aay, Neel Kumar Anand, Charles M. Blazey, Owen Joseph Bowles, Joerg Bussenlus, Simona Costanzo, Jeffry Kimo Curtis, Steven Charles DeFina, Larisa Dubenko, Anagha Abhijit Joshi, Abigall R. Kennedy, Angle Inyoung Kim, Elena S. Koltun, Jean-Claire Limun Manalo, Csaba J. Peto, Kenneth D. Rice, Tsze H. Tsang
Filed: 8 Oct 19
Utility
Combinations of Cabozantinib and Atezolizumab to Treat Cancer
20 Nov 19
This invention relates to the combination of cabozantinib and atezolizumab to treat locally advanced or metastatic solid tumors, particularly advanced urothelial cancer or renal cell carcinoma.
Gisela Schwab, Christian Scheffold, Colin Hessel
Filed: 18 Jan 18